GLP-3 R
Also known as: GLP-3 R, GLP3R, LY3437943
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Last updated
Mechanism of Action
GLP-3 R is a synthetic peptide that acts as a balanced agonist at three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). GLP-1R and GIPR agonism enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite via hypothalamic and brainstem circuits, while glucagon receptor agonism increases energy expenditure and hepatic lipid mobilization. The added glucagon component is thought to drive greater fat oxidation and metabolic rate compared with dual GLP-1/GIP agonists, producing larger reductions in body weight and hepatic fat in clinical trials.
- Half-life
- Approximately 6 days, supporting once-weekly dosing
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Produced large mean body-weight reductions in phase 2 trials
- Triple agonism may raise energy expenditure via glucagon receptor
- Improves glycemic control and HbA1c in type 2 diabetes studies
- Reduces hepatic fat content relevant to fatty liver disease
- Once-weekly dosing schedule
- Improves cardiometabolic risk markers in trial populations
Potential Side Effects
- Nausea, vomiting, and diarrhea, especially during dose escalation
- Constipation and reduced appetite
- Increased heart rate
- Potential transient rise in fasting glucose at higher doses (glucagon effect)
- Injection-site reactions
Common Dosing
Research-use only and not medical advice; clinical trials escalated doses gradually up to roughly 12 mg subcutaneously once weekly, beginning at much lower starting doses to limit gastrointestinal effects.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2
- Pregnancy and breastfeeding
- History of pancreatitis
- Severe gastrointestinal disease such as gastroparesis
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
Tirzepatide
A dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with weight-loss results that often exceed GLP-1-only agents.
Semaglutide
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
- View
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
2022
- View
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
2022